相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people
Anoop Dinesh Shah et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Ilkka Tikkanen et al.
DIABETES CARE (2015)
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
Bernard Zinman et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica et al.
CIRCULATION (2014)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Hans-Ulrich Haering et al.
DIABETES CARE (2014)
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2014)
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
C. S. Kovacs et al.
DIABETES OBESITY & METABOLISM (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
John J. V. McMurray et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Anthony H. Barnett et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology
Richard M. Cubbon et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trial
Hans-Ulrich Haering et al.
DIABETES CARE (2013)
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
T. Heise et al.
DIABETES OBESITY & METABOLISM (2013)
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Lars Ryden et al.
EUROPEAN HEART JOURNAL (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Roden et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
John J. V. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative
Claudio Ronco et al.
EUROPEAN HEART JOURNAL (2010)
Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. M. Turnbull et al.
DIABETOLOGIA (2009)
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials
Rodrigo M. Lago et al.
LANCET (2007)
Insulin-treated dia betes is associated with a marked increase in mortality in patients with advanced heart failure
S Smooke et al.
AMERICAN HEART JOURNAL (2005)
Heart failure prevalence, incidence, and mortality in the elderly with diabetes
AG Bertoni et al.
DIABETES CARE (2004)